Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene

Oncogene

Volumn 28, Issue 48, 2009, Pages 4225-4236

  Jaskelioff, M ^a   Song, W ^b   Xia, J ^b   Liu, C ^b   Kramer, J ^b   Koido, S ^c   Gendler, S J ^d   Calderwood, S K ^a   Gong, J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Mammary carcinoma; MUC1; PyMT; Telomerase; Telomeres

Indexed keywords

MUCIN 1; TELOMERASE; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; TELOMERE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; ONCOGENES; RNA; TELOMERASE; TELOMERE;

MUS; POLYOMAVIRUS;

EID: 71349088358     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.268     Document Type: Article

References (54)

1. Argilla D, Chin K, Singh M, Hodgson JG, Bosenberg M, de Solorzano CO et al. (2004). Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. Cancer Cell 6: 373-385.
2. Artandi SE, Alson S, Tietze MK, Sharpless NE, Ye S, Greenberg RA et al. (2002). Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 99: 8191-8196.
3. Artandi SE, Attardi LD. (2005). Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 331: 881-890.
4. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L et al. (2000). Telomere dysfunction promotes non-reciprocal transloca-tions and epithelial cancers in mice. Nature 406: 641-645.
5. Artandi SE, DePinho RA. (2000). A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10: 39-46.
6. Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA. (2007). Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev 21: 206-220.
7. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA et al. (1997). Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
8. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.
9. Canela A, Klatt P, Blasco MA. (2007). Telomere length analysis. Methods Mol Biol 371: 45-72.
10. Canela A, Martin-Caballero J, Flores JM, Blasco MA. (2004). Constitutive expression of tert in thymocytes leads to increased incidence and dissemination of T-cell lymphoma in Lck-Tert mice. Mol Cell Biol 24: 4275-4293.
11. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. (2003). Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 17: 88-100.
12. Chang S, Multani AS, Cabrera NG, Naylor ML, Laud P, Lombard D et al. (2004). Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 36: 877-882.
13. Chen D, Koido S, Li Y, Gendler S, Gong J. (2000). T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat 60: 107-115.
14. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O et al. (2003). Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109: 300-307.
15. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ et al. (1999). p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97: 527-538.
16. Choudhury AR, Ju Z, Djojosubroto MW, Schienke A, Lechel A, Schaetzlein S et al. (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 39: 99-105.
17. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS et al. (2007). Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8: 497-503.
18. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB et al. (1992). Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921-1929.
19. Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. (1994). Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J Virol 68: 3410-3414
20. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T et al. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198.
21. de Lange T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110.
22. DePinho RA, Polyak K. (2004). Cancer chromosomes in crisis. Nat Genet 36: 932-934.
23. Espejel S, Klatt P, Menissier-de Murcia J, Martin-Caballero J, Flores JM, Taccioli G et al. (2004). Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs. J Cell Biol 167: 627-638.
24. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. (2003). Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 63: 5021-5027.
25. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J et al. (1990). Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293.
26. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. (2000). Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26: 114-117.
27. Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL et al. (2001). Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 20: 2619-2630.
28. Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH et al. (1999). Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97: 515-525.
29. Greider CW, Blackburn EH. (1987). The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51: 887-898.
30. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. (1999). Creation of human tumour cells with defined genetic elements. Nature 400: 464-468.
31. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
32. Hara E, Tsurui H, Shinozaki A, Nakada S, Oda K. (1991). Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem Biophys Res Commun 179: 528-534.
33. Herrera E, Samper E, Martin-Caballero J, Flores JM, Lee HW, Blasco MA. (1999). Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 18: 2950-2960.
34. Khoo CM, Carrasco DR, Bosenberg MW, Paik JH, Depinho RA. (2007). Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci USA 104: 3931-3936.
35. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
36. Martinez P, Siegl-Cachedenier I, Flores JM, Blasco MA. (2009). MSH2 deficiency abolishes the anticancer and pro-aging activity of short telomeres. Aging Cell 8: 2-17.
37. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. (2007). Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971.
38. McClintock B. (1941). The stability of broken ends of chromosomes in Zea mays. Genetics 26: 234-282.
39. Meeker AK, Argani P. (2004). Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 9: 285-296.
40. O'Hagan RC, Chang S, Maser RS, Mohan R, Artandi SE, Chin L et al. (2002). Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2: 149-155.
41. Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L et al. (2008). Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 29: 747-753.
42. Pulaski BA, Ostrand-Rosenberg S. (1998). Reduction of established spontaneous mammary carcinoma metastases following immu-notherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58: 1486-1493.
43. Qi L, Strong MA, Karim BO, Armanios M, Huso DL, Greider CW. (2003). Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumor-igenesis. Cancer Res 63: 8188-8196.
44. Qi L, Strong MA, Karim BO, Huso DL, Greider CW. (2005). Telomere fusion to chromosome breaks reduces oncogenic trans-locations and tumour formation. Nat Cell Biol 7: 706-711.
45. Rasband WS. (1997-2008). ImageJ. US National Institutes of Health: Bethesda, MD, USA.
46. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. (1998). Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58: 315-321.
47. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C et al. (1999). Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701-712.
48. Siegl-Cachedenier I, Munoz P, Flores JM, Klatt P, Blasco MA. (2007). Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres. Genes Dev 21: 2234-2247.
49. Sun B, Huang Q, Liu S, Chen M, Hawks CL, Wang L et al. (2004). Progressive loss of malignant behavior in telomerase-negative tumorigenic adrenocortical cells and restoration of tumorigenicity by human telomerase reverse transcriptase. Cancer Res 64: 6144-6151.
50. Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A et al. (2008). Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 135: 609-622.
51. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Kruger A et al. (2008). Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27: 4191-4199.
52. Vaziri H, Benchimol S. (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8: 279-282.
53. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ et al. (2003). Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 170: 1980-1986.
54. Zhu J, Wang H, Bishop JM, Blackburn EH. (1999). Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 96: 3723-3728